Role of Immunotherapy Expanding in Head and Neck Cancer – OncLive
OncLive |
Role of Immunotherapy Expanding in Head and Neck Cancer
OncLive The field already has 2 immunotherapy approvals with PD-1 agents. Pembrolizumab (Keytruda) was granted an accelerated approval by the FDA in August 2016 for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma … |
